The objective of this study is to investigate the safety and effectiveness in routine clinical practice and actual clinical setting for all patients with rheumatoid arthritis (RA) treated with peficitinib.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety assessed by frequency of adverse events (AEs)
Timeframe: Up to 52 weeks
Safety assessed by frequency of adverse drug reactions (ADRs)
Timeframe: Up to 52 weeks
Safety assessed by frequency of serious infections
Timeframe: Up to 156 weeks
Safety assessed by frequency of malignancy
Timeframe: Up to 156 weeks
Safety assessed by frequency of events leading to death
Timeframe: Up to 156 weeks
Safety assessed by frequency of AEs of special interests
Timeframe: Up to 156 weeks
Safety assessed by frequency of serious adverse events (SAEs)
Timeframe: Up to 156 weeks
Safety assessed by frequency of serious adverse drug reactions (SADRs)
Timeframe: Up to 156 weeks
Disease activity score (DAS28) - C-reactive protein (CRP)
Timeframe: Up to 52 weeks
DAS28- erythrocyte sedimentation rate (ESR) score
Timeframe: Up to 52 weeks
Simplified Disease Activity Index (SDAI) score
Timeframe: Up to 52 weeks
Clinical Disease Activity Index (CDAI) score
Timeframe: Up to 52 weeks
Tender Joint Count (TJC) (28 joints)
Timeframe: Up to 52 weeks
Swollen Joint Count (SJC) (28 joints)
Timeframe: Up to 52 weeks
Erythrocyte sedimentation rate (ESR)
Timeframe: Up to 52 weeks
C-reactive protein (CRP)
Timeframe: Up to 52 weeks
Subject's Global Assessment of Arthritis (SGA) (visual analog scale (VAS))
Timeframe: Up to 52 weeks
Physician's Global Assessment of Arthritis (PGA) (VAS)
Timeframe: Up to 52 weeks
European League Against Rheumatism (EULAR) Response Criteria
Timeframe: Up to 52 weeks
Percentage of participants achieving DAS28-CRP scores for remission
Timeframe: Up to 52 weeks
Percentage of participants achieving DAS28-ESR scores for remission
Timeframe: Up to 52 weeks